Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. 2015

Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany leonid.karawajew@charite.de.

Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004253 DNA Nucleotidylexotransferase A non-template-directed DNA polymerase normally found in vertebrate thymus and bone marrow. It catalyzes the elongation of oligo- or polydeoxynucleotide chains and is widely used as a tool in the differential diagnosis of acute leukemias in man. EC 2.7.7.31. Terminal Addition Enzyme,Terminal Deoxyribonucleotidyltransferase,Deoxynucleotidyl Transferase,Deoxynucleotidyltransferase,Desoxynucleotidyl Transferase,Desoxynucleotidyltransferase,Tdt Antigen,Terminal Deoxynucleotidyl Transferase,Terminal Deoxyribonucleotidyl Transferase,Addition Enzyme, Terminal,Antigen, Tdt,Deoxynucleotidyl Transferase, Terminal,Deoxyribonucleotidyl Transferase, Terminal,Deoxyribonucleotidyltransferase, Terminal,Enzyme, Terminal Addition,Nucleotidylexotransferase, DNA,Transferase, Deoxynucleotidyl,Transferase, Desoxynucleotidyl,Transferase, Terminal Deoxynucleotidyl,Transferase, Terminal Deoxyribonucleotidyl
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
June 2005, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
August 2010, Klinicheskaia laboratornaia diagnostika,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
May 2006, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
January 2001, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
December 2014, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
April 2022, Zhongguo shi yan xue ye xue za zhi,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
January 2006, Managed care (Langhorne, Pa.),
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
January 2004, Acta haematologica,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
September 1990, Journal of immunological methods,
Leonid Karawajew, and Michael Dworzak, and Richard Ratei, and Peter Rhein, and Giuseppe Gaipa, and Barbara Buldini, and Giuseppe Basso, and Ondrej Hrusak, and Wolf-Dieter Ludwig, and Günter Henze, and Karl Seeger, and Arend von Stackelberg, and Ester Mejstrikova, and Cornelia Eckert
December 1991, American journal of hematology,
Copied contents to your clipboard!